Treatment of Liver Fibrosis after Hepatitis B with TCM Combined with NAs Evaluated by Noninvasive Diagnostic Methods: A Retrospective Study

Li Ying; Zhou Pan; Zhu Lin-Yi; Hong Wan-Er; Wang De-He; Zhang Zhen-Jie; Chu Xi; Wang Yi-Qun; Shen Tian-Bai; Zhang Wei

doi:10.1155/2023/5711151

Treatment of Liver Fibrosis after Hepatitis B with TCM Combined with NAs Evaluated by Noninvasive Diagnostic Methods: A Retrospective Study

Evid Based Complement Alternat Med. 2023 Apr 25:2023:5711151. doi: 10.1155/2023/5711151. eCollection 2023.

Authors

Li Ying¹, Zhou Pan¹, Zhu Lin-Yi², Hong Wan-Er¹, Wang De-He¹, Zhang Zhen-Jie¹, Chu Xi¹, Wang Yi-Qun¹, Shen Tian-Bai¹, Zhang Wei¹

Affiliations

¹ Department of Hepatology, Longhua Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
² Changhai Community Health Service Center, Yangpu District of Shanghai, Shanghai, China.

Abstract

Objective. Chronic hepatitis B liver fibrosis is an important intermediate link in the development of liver cirrhosis. A retrospective cohort study was conducted in Longhua Hospital affiliated to the Shanghai University of Traditional Chinese Medicine in order to prove whether integrated traditional Chinese and Western medicine could improve the incidence of CHB complications and clinical prognosis. There are 130 patients with hepatitis B liver fibrosis (being treated from 2011-2021) included in the study, and the patients were divided into 64 TCM users (NAs combined with TCM) and 66 TCM nonusers (NAs antiviral therapy). The serum noninvasive diagnostic model (APRI, FIB-4) and LSM value were used to classify the stages of fibrosis. The results showed that the LSM value was decreased significantly in TCM users compared with TCM nonusers (40.63% versus 28.79%). Indicators of FIB-4 and APRI of TCM users have improved significantly compared with that of TCM nonusers (32.81% versus 10.61% and 35.94% versus 24.24%). The AST, TBIL, and HBsAg levels in TCM users were lower than those in TCM nonusers, and the HBsAg level was inversely correlated with the CD3+, CD4+, and CD8+ in TCM users. The PLT and spleen thickness of TCM users also were improved considerably. The incidence rate of end-point events (decompensated cirrhosis/liver cancer) in TCM nonusers was higher than that of TCM users (16.67% versus 1.56%). The long course of the disease and a family history of hepatitis B were the risk factors for disease progression, and long-term oral administration of TCM was the protective factor. As a result, the serum noninvasive fibrosis index and imaging parameters in TCM users were lower than those of TCM nonusers. Patients in the treatment of NAs combined with TCM had better prognoses such as a lower HBsAg level, a more stable lymphocyte function, and a lower incidence of end-point events. The present findings suggest the effect of TCM combined with NAs in the treatment of chronic hepatitis B liver fibrosis is better than that of single drug treatment.